Literature DB >> 19009975

Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.

M Feuth1, J Wim Brandsma, W R Faber, B Bhattarai, T Feuth, A M Anderson.   

Abstract

INTRODUCTION: Erythema nodosum leprosum (ENL) is an inflammatory reaction, which may occur in the course of leprosy and may result in nerve function impairment and subsequent disability.
METHODS: This retrospective study explores demographic and disease specific parameters. Severity of ENL was assessed using the Reaction Severity Scale (RSS). Records of 94 patients were reviewed. The study reports also on the treatment of 76 of these patients who were treated with prednisolone alone or thalidomide in addition to prednisolone. RESULTS Thirty percent of patients presented with ENL at time of diagnosis; 41% developed ENL-reaction in the first year of MDT. Forty-eight percent of patients were treated for ENL-reaction for less than 12 months; 13% for more than 5 years. High RSS-scores correlated with a longer duration of treatment. In group A (prednisolone) 51.7% and in group B (prednisolone and thalidomide) 76.6% of patients were male. Age, leprosy classification, delay of multidrug treatment (MDT) and interval between MDT and first ENL-symptoms did not differ significantly in both groups. Median duration of ENL-treatment was 15 months in group A versus 38 months in group B (P < 0.001). At the start of treatment, ENL-reaction was less severe in group A (RSS = 12) than in group B (RSS = 18; P = 0.003). DISCUSSION: ENL-symptoms may be of help in the early diagnosis and adequate treatment of ENL. Characterisation of (sub) groups of patients with ENL based on presence and severity of symptoms is important for future prospective studies to better evaluate the efficacy of interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009975

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  5 in total

1.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

2.  ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum.

Authors:  Stephen L Walker; Marivic Balagon; Joydeepa Darlong; Shimelis N Doni; Deanna A Hagge; Vikas Halwai; Annamma John; Saba M Lambert; Armi Maghanoy; Jose A C Nery; Kapil D Neupane; Peter G Nicholls; Vivek V Pai; Pawan Parajuli; Anna M Sales; Euzenir Sarno; Mahesh Shah; Digafe Tsegaye; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

3.  A critical appraisal of the ENLIST severity scale for erythema nodosum leprosum.

Authors:  Bhushan Kumar; Hitaishi Mehta; Tarun Narang; Sunil Dogra
Journal:  PLoS Negl Trop Dis       Date:  2022-04-26

4.  A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.

Authors:  Stephen L Walker; Anna M Sales; C Ruth Butlin; Mahesh Shah; Armi Maghanoy; Saba M Lambert; Joydeepa Darlong; Benjamin Jewel Rozario; Vivek V Pai; Marivic Balagon; Shimelis N Doni; Deanna A Hagge; José A C Nery; Kapil D Neupane; Suwash Baral; Biliom A Sangma; Digafe T Alembo; Abeba M Yetaye; Belaynesh A Hassan; Mohammed B Shelemo; Peter G Nicholls; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2017-07-03

5.  The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.

Authors:  Edessa Negera; Stephen L Walker; Kidist Bobosha; Yonas Bekele; Birtukan Endale; Azeb Tarekegn; Markos Abebe; Abraham Aseffa; Hazel M Dockrell; Diana N Lockwood
Journal:  Front Immunol       Date:  2018-02-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.